Drug vignettes: Tocilizumab, CEBM (updated 20th January 2021)
Patients with severe COVID-19 can develop cytokine release syndrome ( “cytokine storm”) and are reported to have high circulating IL-6 concentrations. Tocilizumab is a recombinant humanized anti-human IgG1 monoclonal antibody directed against the interleukin-6 receptor (IL-6R). It has therefore been proposed to be of value in the management of severe COVID-19. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 22, 2021 Category: Consumer Health News Source Type: news

Tocilizumab Does Not Improve Outcomes in Severe COVID - 19
Tocilizumab plus standard care no better for improving clinical outcomes at 15 days and may increase mortality (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 21, 2021 Category: Respiratory Medicine Tags: Infections, Nursing, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

Tocilizumab Does Not Improve Outcomes in Severe COVID-19
THURSDAY, Jan. 21, 2021 -- Tocilizumab plus standard care is not superior to standard care alone for improving clinical outcomes among patients with severe or critical COVID-19 and may increase mortality, according to a study published online Jan.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 21, 2021 Category: Pharmaceuticals Source Type: news

Arthritis drug hailed by Boris Johnson may not help battle Covid-19
The research from Brazil found 11 of 65 people treated with tocilizumab died 15 days after getting the drug compared to just two for those who did not get the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - January 21, 2021 Category: Consumer Health News Source Type: news

Arthritis Drug Tocilizumab Flops as COVID-19 Treatment
THURSDAY, Jan. 21, 2021 -- The arthritis drug tocilizumab doesn ' t help hospital patients with severe COVID-19, according to a new study that contradicts earlier research suggesting that it might aid recovery. In fact, patients receiving tocilizumab... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 21, 2021 Category: General Medicine Source Type: news

New trial finds arthritis drug no better than standard care for severe covid-19
(BMJ) Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds a new trial published byThe BMJ today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 20, 2021 Category: International Medicine & Public Health Source Type: news

COVID-19 rapid evidence summary: Tocilizumab for COVID-19 [ES33] NICE (published 15th January 2021)
Unpublished preliminary evidence from the REMAP ‑CAP study has suggested that tocilizumab is beneficial in adults with severe COVID‑19 who are critically ill and receiving respiratory or cardiovascular organ support in an intensive care setting (all randomised within 24 hours of starting organ support). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 15, 2021 Category: Consumer Health News Source Type: news

Arthritis drugs effective in improving survival in sickest COVID-19 patients, NIHR
Results from the REMAP-CAP clinical trial evaluated the effect of treatments on a combination of survival and length of time patients need support in an intensive care unit (ICU). Patients receiving tocilizumab and a second drug called sarilumab - both types of immune modulators - have a significant impact on patient survival and can reduce the relative risk of death by 24% when administered to patients within 24 hours of entering intensive care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 14, 2021 Category: Consumer Health News Source Type: news

UK Approves Arthritis Drugs for Critically Ill COVID-19 Patients
The immunosuppressive drugs tocilizumab and sarilumab improved survival and recovery time of intensive care COVID-19 patients, according to a preprint. (Source: The Scientist)
Source: The Scientist - January 11, 2021 Category: Science Tags: News & Opinion Source Type: news

Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults), MHRA (issued 8th January 2021)
The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if available) following the criteria defined in this interim position statement. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news

Covid Deaths Lowered in Trial of Tocilizumab and Sarilumab
The big dip in mortality shown in the trial of about 800 patients has caught some experts by surprise because previous studies of the drugs showed little benefit. (Source: NYT Health)
Source: NYT Health - January 8, 2021 Category: Consumer Health News Authors: Katherine J. Wu Tags: Clinical Trials Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) medRxiv Dexamethasone (Drug) Research Immune System Deaths (Fatalities) your-feed-healthcare Source Type: news

Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients   Roche, Sanofi Arthritis Drugs Reduce Death Rates Among Sickest COVID-19 Patients  
Treating critically ill COVID-19 patients with Roche ' s Actemra or Sanofi ' s Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - January 8, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news

New Covid drugs ‘significantly’ reduce mortality in critically ill, study finds
Tocilizumab and sarilumab both shown to improve chances of survival and recovery in patients admitted to intensive care (Source: Reuters: Health)
Source: Reuters: Health - January 8, 2021 Category: Consumer Health News Source Type: news

Covid UK: Arthritis drugs that cut ICU death risk 24% available now
The PM said the anti-inflammatory drugs tocilizumab and sarilumab would be made available across the UK with immediate effect, 'potentially saving thousands of lives'. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2021 Category: Consumer Health News Source Type: news

Arthritis drugs found to reduce risk of death in severe Covid-19 cases
Immunosuppressants tocilizumab and sarilumab also reduce stays in intensive care by at least seven days on average (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - January 7, 2021 Category: Pharmaceuticals Source Type: news